Abbott's U.S. launch of high-volume Architect chemiluminescence analyzer slated for early 1998.

ABBOTT U.S. LAUNCH OF ARCHITECT i2000 AUTOMATED IMMUNOASSAY ANALYZER slated for early 1998, the company says. Abbott Laboratories is conducting trials of the next-generation Architect i2000, the flagship of a line of low- to high-volume modular analyzers. A 510(k) for the chemiluminescence-based system has not yet been submitted.